Talk to us

A look back and a look forward

3/2, 2021

A new year has already begun, filled with new opportunities and positive expansions. We hope it will be a brighter year as well, knowing that 2020 was a challenging one for all of us. Both privately and at work, we have all been affected by the pandemic in many ways.
That said, Immuneed has been fortunate. We have had the privilege of being able to conduct our business and continue developing it. Besides expanding our products and services, we have been able to grow as an organization, and we have adopted new ways of staying connected to the market and our customers.
One important milestone for us has been the implementation of a new corporate identity and the formulation of our core business. Immuneed has changed in recent years, and our focus is now fully on the service we offer to you, based on our unique technological platform and internal know-how. As you probably know, our customers across Europe turn to us with a breadth of needs, ranging from standardized analysis to product-tailored projects. Over the past year, we have gained even more valuable experience and knowledge through our work with different products, having evaluated and analyzed everything from peptides and small molecules to monoclonal and bispecific antibodies, CAR-Ts, nanoparticles and virus-based products. Being driven by innovation, we also have the pleasure of having several exciting assays in our pipeline. Keep an eye open for new offerings during the year, the first of which should appear later this spring. In the meantime, we can offer you some teasers:

  • Additional assays of platelet function to better understand the impact on hemostasis, bleeding, and thrombosis.
  • An oncology disease model with target cells spiked into the test system to recreate the disease state in vivo.

When it comes to our innovation, but also to our business, you as an Immuneed customer are always in focus. You are our most asset, and your constructive, straightforward feedback is vital to us. That input is what ensures that we move in the right direction. Our knowledgeable team is ready and happy to support you, wherever you are in your important drug development phase. On that final note, I appreciate you are taking the time to read these reflections on last year’s achievements and our key plans for 2021. On behalf of the whole Immuneed team, I thank for your engagement, your feedback, and your business collaboration. Please stay safe.

Yours sincerely,
Camilla Oldgren
CEO

IMN-PR-04-2021